10005-ANGI-1 REGULATION OF ALTERNATIVE ANGIOGENIC FACTORS IN BEVACIZUMAB THERAPY FOR GLIOBLASTOMA
Taketo Ezaki, Toshihide Tanaka, Ryota Tamura, Yohei Yamamoto, Jun Takei, Yukina Morimoto, Ryotaro Imai, Yuki Kuranari, Yasuharu Akasaki, Yuichi Murayama, Keisuke Miyake, Hikaru Sasaki · 2023
Read 10005-ANGI-1 REGULATION OF ALTERNATIVE ANGIOGENIC FACTORS IN BEVACIZUMAB THERAPY FOR GLIOBLASTOMA by Taketo Ezaki, Toshihide Tanaka, Ryota Tamura, Yohei Yamamoto, Jun Takei, Yukina Morimoto, Ryotaro Imai, Yuki Kuranari, Yasuharu Akasaki, Yuichi Murayama, Keisuke Miyake, Hikaru Sasaki (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10710573.txt.
Description
Taketo Ezaki and eleven co-authors published a 2023 study of why brain tumours resist a drug that starves them of blood vessels. Glioblastoma patients often receive bevacizumab, which blocks one growth signal for vessels. Tumours adapt by turning up other signals, and this team measured those backups in human tissue.
They examined 54 tumours taken before treatment, during response, and after relapse, including paired samples from the same patients. One vessel factor rose while the drug worked, and two others rose at relapse. In paired samples, the first factor was higher after relapse than before treatment. The findings are early clinic evidence that escape routes shift over time. Knowing the sequence may help doctors time combination treatments.
Catalog record
| CREATOR | Taketo Ezaki, Toshihide Tanaka, Ryota Tamura, Yohei Yamamoto, Jun Takei, Yukina Morimoto, Ryotaro Imai, Yuki Kuranari, Yasuharu Akasaki, Yuichi Murayama, Keisuke Miyake, Hikaru Sasaki |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |